SEC Form 4

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-028									

OMB Number:	3235-0287
Estimated average burg	len
hours per response:	0.5

I I Name and Address of Reporting Feison		Person*	2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Kiamer	KODEIL			Director	10% Owner				
				X Officer (give					
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	below)	below)				
	Last) (First) (Middle) 00 PROFESSIONAL DR, SUITE 400		04/01/2016	EVP, Corp	orate Services Divisi				
400 PRO	FESSIONAL DR, S	UITE 400							
(Otres at)			4. If Amendment, Date of Original Filed (Month/Day/Year)		Group Filing (Check Applicable				
(Street)				Line)					
GAITHE	RSBURG MD	20879		X Form filed by	y One Reporting Person				
				Form filed by	y More than One Reporting				
(0:+.)	(0++++)	(7:)		Person					
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(
Common Stock ⁽¹⁾	04/01/2016		М		11,531	Α	\$14.41	91,607	D	
Common Stock ⁽¹⁾	04/01/2016		S		11,531	D	\$35.49 ⁽⁵⁾	80,076	D	
Common Stock ⁽²⁾	04/01/2016		М		3,939	A	\$14.6 7	84,015	D	
Common Stock ⁽²⁾	04/01/2016		S		3,939	D	\$35.74(6)	80,076	D	
Common Stock ⁽³⁾	04/01/2016		М		17,354	A	\$28.09	97,430	D	
Common Stock ⁽³⁾	04/01/2016		S		17,354	D	\$35.48(7)	80,076	D	
Common Stock ⁽⁴⁾	04/01/2016		М		5,503	A	\$29	85,579	D	
Common Stock ⁽⁴⁾	04/01/2016		S		5,503	D	\$35.66 ⁽⁸⁾	80,076	D	
Common Stock ⁽⁹⁾	04/01/2016		S		445	D	\$35.93 ⁽¹⁰⁾	79,631	D	
Common Stock ⁽⁹⁾	04/01/2016		S		1,855	D	\$35.8 ⁽¹¹⁾	77,776	D	
Common Stock ⁽⁹⁾	04/01/2016		S		2,945	D	\$35.73 ⁽¹²⁾	74,831	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Numl of Derivati Securiti Acquire (A) or Dispose of (D) (I 3, 4 and	ive ies ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		ecurities Derivative erlying Security vative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option ⁽¹⁾	\$14.41	04/01/2016		М		11,531		(13)	11/04/2019	Common Stock	11,531	\$ <mark>0</mark>	11,531	D	
Stock Option ⁽²⁾	\$14.67	04/01/2016		М		3,939		(14)	03/11/2020	Common Stock	3,939	\$ <mark>0</mark>	3,940	D	
Stock Option ⁽³⁾	\$28.09	04/01/2016		М		17,354		(15)	03/10/2021	Common Stock	17,354	\$0	34,708	D	
Stock Option ⁽⁴⁾	\$29	04/01/2016		М		5,503		(16)	03/09/2022	Common Stock	5,503	\$ <mark>0</mark>	27,514	D	

Explanation of Responses:

1. Consists of an option granted under the company's stock incentive plan on November 5, 2012.

2. Consists of an option granted under the company's stock incentive plan on March 12, 2013.

3. Consists of an option granted under the company's stock incentive plan on March 11, 2014.

4. Consists of an option granted under the company's stock incentive plan on March 10, 2015.

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.11 to \$36.34, inclusive.

6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.37 to \$36.32, inclusive.

7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.07 to \$36.35, inclusive.

8. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.12 to \$36.42, inclusive.

9. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

10. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.91 to \$36.00, inclusive.

11. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.50 to \$36.13, inclusive.

12. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.50 to \$36.32, inclusive.

- 13. The option vested in three equal installments in November 2013, 2014 and 2015.
- 14. The option vest in three equal installments in March 2014, 2015 and 2016.
- 15. The option vest in three equal installments in March 2015, 2016 and 2017.
- 16. The option vest in three equal installments in March 2016, 2017 and 2018.

<u>/s/ Eric Burt, attorney-in-fact</u>0

** Signature of Reporting Person

<u>04/05/2016</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.